NCT00349336View on ClinicalTrials.gov

A Study of Avastin (Bevacizumab) in Combination With XELOX or FOLFOX-4 in Patients With Metastatic Colorectal Cancer.

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

November 30, 2008

Study Completion Date

November 30, 2008

Conditions

Colorectal Cancer

Interventions

DRUG

bevacizumab [Avastin]

7.5mg/kg iv on day 1 of each 3 week cycle

DRUG

XELOX

As prescribed

DRUG

bevacizumab [Avastin]

5mg/kg iv on day 1 of each 2 week cycle

DRUG

FOLFOX-4

As prescribed

Trial Locations (7)

2031

Sydney

3065

Fitzroy

3128

Box Hill

L6R 3J7

Brampton

L8V 5C2

Hamilton

M5G 2M9

Toronto

Unknown

Christchurch

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY

NCT00349336 - A Study of Avastin (Bevacizumab) in Combination With XELOX or FOLFOX-4 in Patients With Metastatic Colorectal Cancer. | Biotech Hunter | Biotech Hunter